Patrick John Finn Sells 2,422 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 2,422 shares of the company’s stock in a transaction dated Thursday, January 23rd. The stock was sold at an average price of $50.17, for a total value of $121,511.74. Following the sale, the chief operating officer now owns 272,044 shares in the company, valued at $13,648,447.48. The trade was a 0.88 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Patrick John Finn also recently made the following trade(s):

• On Friday, January 3rd, Patrick John Finn sold 229 shares of Twist Bioscience stock. The stock was sold at an average price of $45.59, for a total value of $10,440.11.
• On Monday, November 11th, Patrick John Finn sold 10,340 shares of Twist Bioscience stock. The shares were sold at an average price of $48.00, for a total value of $496,320.00.
• On Wednesday, November 6th, Patrick John Finn sold 6,239 shares of Twist Bioscience stock. The stock was sold at an average price of $44.60, for a total transaction of $278,259.40.
• On Monday, November 4th, Patrick John Finn sold 2,681 shares of Twist Bioscience stock. The shares were sold at an average price of $41.56, for a total transaction of $111,422.36.

Twist Bioscience Stock Down 3.4 %

Shares of Twist Bioscience stock opened at $52.23 on Tuesday. The stock has a market capitalization of $3.10 billion, a price-to-earnings ratio of -14.51 and a beta of 1.85. Twist Bioscience Co. has a twelve month low of $27.41 and a twelve month high of $60.90. The company has a 50-day simple moving average of $47.62 and a two-hundred day simple moving average of $46.37.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of TWST. Wilmington Savings Fund Society FSB acquired a new stake in Twist Bioscience during the third quarter worth about $34,000. Signaturefd LLC raised its position in Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after purchasing an additional 306 shares in the last quarter. Beaird Harris Wealth Management LLC bought a new stake in Twist Bioscience during the third quarter worth $95,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Twist Bioscience by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after purchasing an additional 381 shares in the last quarter. Finally, KBC Group NV increased its stake in shares of Twist Bioscience by 71.4% in the 4th quarter. KBC Group NV now owns 2,942 shares of the company’s stock valued at $137,000 after purchasing an additional 1,226 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Robert W. Baird upped their target price on shares of Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a report on Tuesday, November 19th. Wolfe Research began coverage on Twist Bioscience in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective for the company. Barclays decreased their target price on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a report on Tuesday, November 19th. Scotiabank raised their price target on Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a report on Tuesday, November 19th. Finally, TD Cowen reiterated a “buy” rating and issued a $58.00 price objective on shares of Twist Bioscience in a report on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $51.90.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.